Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

3(42.9%)

Phase 2

3(42.9%)

Phase 1

1(14.3%)

7Total

Phase 3(3)

Phase 2(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06040346Phase 2Active Not Recruiting

Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum

Role: lead

NCT05679479Phase 3Completed

Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19

Role: lead

NCT05813587Phase 3Completed

To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19

Role: lead

NCT04327310Phase 1Withdrawn

Clinical Study of Meplazumab to Treat With Malaria

Role: lead

NCT05679492Phase 3Withdrawn

Study on the Safety and Efficacy of Meplazumab for Injection Patients COVID-19

Role: lead

NCT04586153Phase 2Completed

Study to Assess the Effect of Meplazumab on COVID-19

Role: lead

NCT05113784Phase 2Completed

the Safety and Efficacy of Meplazumab in Patients With COVID-19

Role: lead

All 7 trials loaded